Ascendis agrees BioMarin Yuviwel royalty terms; infant reACHin data set for ESPE 2026
Ascendis Pharma agreed to pay BioMarin royalties on Yuviwel sales, with patent and litigation claims dismissed. The company will present infant reACHin TransCon CNP data at ESPE 2026 and faced modest analyst target trims from multiple firms.
Ascendis Pharma A/S (NASDAQ:ASND) agreed to pay BioMarin royalties on Yuviwel sales, while patent and litigation claims were dismissed. The company also said it will present infant reACHin TransCon CNP data at ESPE 2026. Morgan Stanley, Jefferies, BofA and Stifel each trimmed their price targets.